Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Full description
Immune checkpoint inhibitors have been shown to increase survival in metastatic solid tumor patients when compared to the previously standard of care chemotherapy. Epidemiologic studies of American Indian cancer patients demonstrated having significantly worse survival when compared with Caucasians when controlled for age, sex, alcohol abuse, smoking, insurance, and disease stage.
There are no current studies specifically examining the American Indian population receiving treatment with immune checkpoint inhibitors. The aim is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- above age 18,
- histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used
- received immunotherapy as part of their treatment
- Self-identified American Indian in ethnicity
- Patients at the Stephenson Cancer Center between 2015 to 2021
Exclusion criteria
- patients who did not receive immune checkpoint inhibitor therapy
Trial design
72 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal